Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)

This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL). ORIENT-4 is a multicenter, single-arm, phase 2 clinical trial (NCT03228836). Patients with r/r ENKTL who failed...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Rong, Fan, Lei, Song, Yongping, Hu, Yu, Zhang, Wei, Wang, Yafei, Xu, Wei, Li, Jianyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548511/
https://www.ncbi.nlm.nih.gov/pubmed/34702811
http://dx.doi.org/10.1038/s41392-021-00768-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548511/
https://www.ncbi.nlm.nih.gov/pubmed/34702811
http://dx.doi.org/10.1038/s41392-021-00768-0

Ejemplares similares